Preclinical News and Research

RSS

Three proteins could be new targets for treating stroke, brain and spinal cord injuries

Some mature brain cells can grow new extensions when the amount of three particular proteins on their surface increases, a new study shows.

12 Apr 2007

Pharmacopeia announces positive results in hypertension and diabetic nephropathy trial

Pharmacopeia ( NASDAQ:PCOP ) , an innovator in the discovery and development of novel small molecule therapeutics, today announced positive results from the initial Phase 1 clinical trial of PS433540, the company's lead internal product candidate for the treatment of hypertension and diabetic nephropathy.

11 Apr 2007

Renovis and Pfizer extend research collaboration

Renovis has announced an agreement with Pfizer to extend the term of the companies' worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1.

11 Apr 2007

Atrium Medical receives FDA approval for Omega 3 surgical mesh product

Atrium Medical Corporation is pleased to announce it has obtained US FDA 510(K) approval for a new Omega 3 surgical mesh product called C-QURLite(TM) Mesh.

10 Apr 2007

Efficacy of Guanilib confirmed for inflammatory bowel disease

Callisto Pharmaceuticals has announced additional data confirming efficacy of Guanilib, a first-in-class compound currently being developed for the treatment of inflammatory bowel disease (IBD), in two different standard animal models of experimental colitis.

7 Apr 2007

Boston Scientific announces enrollment in MAPS clinical trial

The MAPS trial (Matrix And Platinum Science) is designed to identify and investigate clinically relevant endpoints for evaluating the efficacy and durability of endovascular treatment of brain aneurysms.

4 Apr 2007

Major step forward for islet transplantation in diabetes patient

Living Cell Technologies Limited has announced it has published evidence outlining the survival and identification of live porcine islet cells and insulin production in a human patient 10 years after receiving a pig islet cell transplant.

2 Apr 2007

Treatment for acute intermittent porphyria

The Center for Applied Medical Research (CIMA) from the University of Navarra and the Amsterdam Molecular Therapeutics BV (AMT) have demonstrated the pre-clinical effectiveness of a treatment against acute intermittent porphyria.

2 Apr 2007

Promising new pain-killing drug

A potential new pain-killing drug developed by medical scientists at the University of Leicester and Ferrara in Italy is to be discussed at a public lecture on 20th March.

19 Mar 2007

Two novel therapies for multiple myeloma

Two novel biologics are currently being investigated for their potential benefit to multiple myeloma patients in separate ongoing clinical trials at NewYork-Presbyterian Hospital/Weill Cornell Medical Center.

14 Mar 2007

Lilly to acquire neuroscience drug discovery co. Hypnion

Eli Lilly and Company and Hypnion, Inc. today announced that they have signed a definitive merger agreement whereby Lilly will acquire Hypnion, a privately held neuroscience drug discovery company focused on sleep disorders.

5 Mar 2007

PPD licenses dyslipidemia statin from Ranbaxy

Ranbaxy Laboratories and PPD, Inc. have announced that PPD has acquired an exclusive worldwide license to develop, manufacture and market Ranbaxy's novel statin for the treatment of dyslipidemia.

27 Feb 2007

MatTek's EpiVaginal successfully used in microbicide/HIV study

MatTek Corp. today announced that its patented EpiVaginal human cell-derived tissue model was successfully used in pre-clinical research investigating HIV infection and microbicide interaction.

27 Feb 2007

Alternative, diet-based method of treating brain cancer

The biologists found that KetoCal, a commercially available high-fat, low-carbohydrate diet designed to treat epilepsy in children, can significantly decrease the growth of brain tumors in laboratory mice.

22 Feb 2007

Cancer Research Technology grants Waypharm option to novel platinum agents

Cancer Research Technology Limited (CRT), the cancer-focused development and commercialisation company, today announce that Waypharm S.A.S (Waypharm) has secured rights to evaluate Thioplatin a novel hypoxia-responsive platinum-based cancer therapy, from CRT.

5 Feb 2007

Effects of prion disease could be reversed if caught early enough

The researchers said that their findings support developing early treatments that aim to reduce levels of prion protein in the brains of people with prion disease.

31 Jan 2007

Institute of Materia Medica and TB Alliance partner to tackle tuberculosis

The Institute of Materia Medica (IMM), a member of the Chinese Academy of Medical Sciences, and the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership accelerating the discovery and development of new TB drugs, today announced plans to pursue a joint research partnership to develop promising, novel anti-tuberculosis agents.

31 Jan 2007

Nventa Bio issued U.S patent for heat shock protein fusion to treat influenza

The patent provides coverage for compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins and their use in immunotherapy.

30 Jan 2007

Access Pharmaceuticals issued U.S. patent

This patent, entitled "O,O'-Amidomalonato and N,O-Amidomalonato Platinum Complexes" is one of a series of patents and patent applications owned by Access which provides intellectual property protection to ProLindac and related tumor-targeted platinum compounds.

30 Jan 2007

CeNeRx BioPharma starts human trials of RIMA antidepressant

CeNeRx BioPharma, Inc. has announced the initiation of human clinical trials of Tyrima, CeNeRx's new drug candidate with a triple mechanism of action for the treatment of depression and anxiety.

30 Jan 2007